Tema Oncology ETF (NASDAQ:CANC) Short Interest Down 92.0% in February

Posted by Joe Tyrrell on Feb 27th, 2025

Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 1,300 shares, a decrease of 92.0% from the January 31st total of 16,300 shares. Based on an average daily volume of 19,000 shares, the days-to-cover ratio is currently 0.1 days.

Tema Oncology ETF Stock Down 0.3 %

NASDAQ:CANC traded down $0.08 on Thursday, hitting $25.39. The stock had a trading volume of 10,520 shares, compared to its average volume of 24,227. The company has a fifty day moving average price of $25.06 and a two-hundred day moving average price of $27.03. Tema Oncology ETF has a 1-year low of $23.97 and a 1-year high of $30.11. The stock has a market cap of $64.74 million, a price-to-earnings ratio of 26.86 and a beta of 1.11.

Tema Oncology ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, December 12th. Investors of record on Wednesday, December 11th were given a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans lifted its holdings in Tema Oncology ETF (NASDAQ:CANC – Free Report) by 25.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 399,509 shares of the company’s stock after purchasing an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned approximately 22.96% of Tema Oncology ETF worth $11,351,000 at the end of the most recent reporting period.

Tema Oncology ETF Company Profile

(Get Free Report)

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.